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ABSTRACT 22 
The Staphylococcus aureus biofilm mode of growth is associated with several chronic 23 
infections that are very difficult to treat due to the recalcitrant nature of biofilms to 24 
clearance by antimicrobials. Accordingly, there is an increasing interest in preventing 25 
the formation of S. aureus biofilms and developing efficient anti-biofilm vaccines. 26 
Given the fact that during a biofilm-associated infection, the first primary interface 27 
between the host and the bacteria is the self-produced extracellular matrix, in this study, 28 
we have analysed the potential of extracellular proteins found in the biofilm matrix to 29 
induce a protective immune response against S. aureus infections. By using proteomic 30 
approaches we characterized the exoproteomes of exopolysaccharide-based and 31 
protein-based biofilm matrices produced by two clinical S. aureus strains. Remarkably, 32 
results showed that independently of the nature of the biofilm matrix, a common core 33 
of secreted proteins is contained in both types of exoproteomes. Intradermal 34 
administration of an exoproteome extract of an exopolysaccharide-dependent biofilm 35 
induced a humoral immune response and elicited the production of IL-10 and IL-17 in 36 
mice. Antibodies against such extract promoted opsonophagocytosis and killing of S. 37 
aureus. Immunization with the biofilm matrix exoproteome significantly reduced the 38 
number of bacterial cells inside a biofilm and on the surrounding tissue, using an in 39 
vivo model of mesh-associated biofilm infection. Furthermore, immunized mice also 40 
showed limited organ colonization by bacteria released from the matrix at the 41 
dispersive stage of the biofilm cycle. Altogether, these data illustrate the potential of 42 
biofilm matrix exoproteins as a promising candidate multivalent vaccine against S. 43 
aureus biofilm-associated infections. 44 
 45 
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INTRODUCTION 47 
Staphylococcus aureus is one of the bacterial species most frequently associated with 48 
biofilm-mediated infections. It can be found as a commensal bacterium on the skin, 49 
nares and mucosa but in some situations, it can become the source of biofilm-related 50 
infections where bacteria grow into multicellular communities attached to a surface and 51 
embedded in a self produced extracellular matrix. S. aureus biofilms can occur on host 52 
tissues such as heart valves (endocarditis) and bone tissue (osteomyelitis) although they 53 
are more frequently related with medical devices (catheters, prostheses, portacaths). 54 
Implanted medical devices are easily coated with plasma and extracellular matrix 55 
proteins such as fibrinogen and fibronectin (1). S. aureus has the ability to bind to these 56 
components via specific receptors and thus, implants become colonized. After primary 57 
attachment to the polymeric surface, bacteria proliferate and accumulate in 58 
multilayered clusters surrounded by an extracellular matrix. The added level of 59 
bacterial resistance inside a biofilm makes these infections difficult to treat and, as a 60 
consequence, in most situations, the device must be surgically removed and replaced 61 
(2). Bacteria from the biofilm can also propagate through detachment of small or large 62 
clumps of cells, or by the release of individual cells allowing bacteria to colonize other 63 
surfaces or tissues far from the original infection site. Bloodstream infections 64 
originating from device-associated infections account for 11% of all health care–65 
associated infections. An estimation of 250,000 catheter-related bloodstream infections 66 
occur in the United States per year, resulting in significant morbidity, mortality, and 67 
costs for health care delivery (3-5). S. aureus is frequently associated with such 68 
infections, and therefore a great effort is being made in order to prevent and/or obtain 69 
effective treatments against this bacterium. Given the fact that bacteria living in a 70 
biofilm express a different set of genes than the same free-living bacteria (6-10), the 71 
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process of antigen selection for the development of an efficient protection against S. 72 
aureus infections should also take into consideration those antigens expressed during 73 
the biofilm growth.  74 
In this respect, a wide variety of extracellular compounds have been identified as 75 
mediators of staphylococcal biofilms such as poly-N-acetyl-glucosamine 76 
exopolysaccharide, PNAG (also named PIA), (11-16), extracellular DNA (eDNA) (17, 77 
18), and different surface-associated proteins including the biofilm-associated protein 78 
(Bap), fibronectin-binding proteins (FnBPs), SasG and Protein A (19-23). Some of 79 
these biofilm mediators have been already proposed as vaccine antigens against S. 80 
aureus infections. Different studies have shown that administration of deacetylated 81 
PNAG conjugated with diphtheria toxin as a carrier protein induces an immunological 82 
response that protects against S. aureus infection (14, 24-26). Furthermore, a recent 83 
study of Cywes-Benttey et al. has shown that PNAG or a structural variant of PNAG is 84 
a conserved surface polysaccharide produced by many pathogenic bacteria, fungi and 85 
protozoal parasites and has demonstrated that passive immunization with antibodies to 86 
PNAG protects mice against both local and systemic infections caused by many of 87 
these pathogens (27). Protein A and FnBPs have also been evaluated for vaccine 88 
development. These antigens generate an immune response that confers partial 89 
protection against S. aureus challenge using systemic infection models (28-30). 90 
However, no evidence has been obtained of the efficiency of these molecules for the 91 
protection against biofilm-based infections.  92 
In the last few years, several studies have demonstrated that biofilms harbor multiple 93 
cell types, resulting in heterogeneous populations that have followed different 94 
developmental pathways (31-33). In this regard, Brady et al. identified immunogenic 95 
cell-wall proteins expressed during a S. aureus biofilm infection and demonstrated 96 
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differing expression patterns for each antigen (34, 35). These authors reasoned that 97 
immunization with a monovalent vaccine would likely mean that only a fraction of the 98 
biofilm would be targeted and thus, the infection would persist (36, 37). Therefore, they 99 
used a quadrivalent vaccine, including four of the identified antigens (glucosaminidase, 100 
an ABC transporter lipoprotein, a conserved hypothetical protein, and a conserved 101 
lipoprotein), combined with antibiotic therapy and demonstrated a reduced S. aureus 102 
biofilm formation on infected tibias, using a chronic osteomyelitis model (37).  103 
Taking into consideration that the biofilm matrix is the first primary interface between 104 
the host and bacteria during a biofilm-associated infection and the relevance of using a 105 
multivalent vaccine for the prevention of biofilm-type infections, in this study we 106 
aimed at investigating whether an extract containing all proteins secreted into the 107 
biofilm matrix might be a potential polyvalent vaccine candidate that protects against S. 108 
aureus biofilm related infections. Thus, we have first isolated and identified the 109 
exoproteins of both PNAG-dependent and independent biofilm matrices produced by a 110 
methicillin sensitive and also a methicillin resistant clinical strain. Notably, 111 
exoproteomes were uniform in that they contained a common set of proteins.  112 
Immunization with a biofilm matrix exoproteins extract effectively reduced biofilm 113 
formation in an in vivo model of mesh-associated biofilm infection, which significantly 114 
correlated with the production of immunoglobulins (IgG and IgM) antibodies with 115 
opsonic activity. Our results also suggested a role for IL-10 and IL-17 cytokines in 116 
biofilm matrix exoproteins-mediated protection. Finally we showed that administration 117 
of this multicomponent protein extract reduces organ colonization conducted by 118 
bacteria released via detachment from the biofilm. 119 
  120 
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Materials and methods 121 
Ethics statement. 122 
All animal studies were reviewed and approved by the ‘‘Comité de Ética, 123 
Experimentación Animal y Bioseguridad’’ of the Universidad Pública de Navarra 124 
(approved protocol PI-019/12). Work was carried out at the Instituto de 125 
Agrobiotecnología building (Idab) under the principles and guidelines described in the 126 
‘‘European Directive 86/609/EEC’’ for the protection of animals used for experimental 127 
purposes. 128 
 129 
Bacterial strains and culture conditions.  130 
Staphylococci were cultured on tryptic soy agar or broth at 37°C supplemented with 131 
glucose (0.25%) or NaCl (3%) when indicated. Strains used in this study were included 132 
in table 1. S. aureus 15981, 132 and 12313 were isolated at the Microbiology 133 
Department of the Clínica Universidad de Navarra (Pamplona, Spain) (23, 38). S. 134 
aureus V329 is a Bap positive strain isolated from a bovine mastitis (19). S. aureus 135 
Newman::bap is a Newman derivative strain containing a chromosomal copy of the 136 
bap gene (39). ISP479r is a derivative of ISP479 with a functional rsbU gene.  As a 137 
biofilm negative strain we used S. aureus Newman strain (ATCC 25905).  138 
 139 
Biofilm formation and protein extracts purification. 140 
Biofilm formation under flow conditions was performed using 60-ml microfermenters 141 
(Pasteur Institute, Laboratory of Fermentation) with a continuous 40 ml h−1 flow of 142 
medium and constant aeration with sterile compressed air (0.3 bar) (40). Submerged 143 
glass slides (spatulas) served as growth substratum. Approximately 108 bacteria from 144 
an overnight culture of each strain grown in the appropriate medium (S. aureus 15981 145 
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was grown in TSB-gluc and S. aureus 132 was grown either in TSB-gluc or TSB-NaCl) 146 
were used to inoculate the microfermenters that were then kept at 37°C for 24 h. The 147 
biofilm formed on the spatula was resuspended in 20 ml of PBS (phosphate-buffered 148 
saline) and vigorously homogenized by vortexing. The suspension was centrifuged at 149 
4800 g for 30 min at 4ºC. Then, the supernatant was collected, centrifuged again at 150 
4800 g for 30 min at 4ºC and filtered through a 0.45 µm filter (SARSTEDT). Matrix 151 
proteins were extracted with trichloroacetic acid 10%. After precipitation, proteins 152 
were dissolved in PBS for quantification with the Bicinchoninic Acid Protein Assay kit 153 
(SIGMA). The planktonic culture exoproteins extract (PLKE) was obtained as follows. 154 
An overnight culture of S. aureus 15981 was diluted 1:100 in an Erlenmeyer flask 155 
containing 50 ml of TSB-gluc medium and was incubated overnight at 37°C with 156 
shaking. The culture was centrifuged at 4800 g. Supernatant was collected and filtered 157 
through a 0.45 µm filter (SARSTEDT). Secreted proteins into the supernatant were 158 
precipitated by the addition of trichloroacetic acid 10%. Proteins extracts were 159 
dissolved in PBS for quantification with the Bicinchoninic Acid Protein Assay kit 160 
(SIGMA). Proteins were resolved using SDS-polyacrylamide gel electrophoresis and 161 
stained with Bio-Rad Silver Stain according to the manufacturer ´s recommendations. 162 
To obtain the bacterial heat extract, a S. aureus 15981 cell suspension containing 108 163 
CFU was heat inactivated at 80°C for 1 h (41).  164 
 165 
Protein identification. 166 
The extracellular protein extract was subjected to tryptic digestion and analyzed as 167 
previously described (22). Briefly, the tryptic peptide mixtures were injected onto a 168 
strong cationic exchange microprecolumn with a flow rate of 30 µl/min as a first-169 
dimension separation. Peptides were eluted from the column as fractions by injecting 170 
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salt of ammonium acetate of increasing concentrations. Ammonium salts were removed 171 
and peptides were analyzed in a continuous acetonitrile gradient on a C18 reversed-172 
phase self-packing nanocolumn. Peptides were eluted (at flow rate of 300 nl/min) from 173 
the reversed-phase nanocolumn to a PicoTip emitter nano-spray needle (New 174 
Objective, Woburn, MA) for real-time ionization and peptide fragmentation on an 175 
Esquire HCT ion trap mass spectrometer (Bruker-Daltonics, Bremen, Germany). Every 176 
1 s, the instrument cycled through acquisition of a full-scan mass spectrum and one 177 
MS/MS spectrum. A 4-Da window (precursor m/z ±2), an MS/MS fragmentation 178 
amplitude of 0.80 V, and a dynamic exclusion time of 0.30 min were used for peptide 179 
fragmentation. 2DnLC was automatically performed on an advanced microcolumn-180 
switching device (Switchos; LC Packings) coupled to an auto-sampler (Famos; LC 181 
Packings) and a nano-gradient generator (Ultimate nano- HPLC; LC Packings). The 182 
software Hystar 2.3 was used to control the whole analytical process. MS/MS spectra 183 
were batch processed by using DataAnalysis 5.1 SR1 and MS BioTools 2.0 software 184 
packages and searched against the S. aureus protein databases using Mascot software 185 
(Matrix Science, London, United Kingdom). The criteria for confirming highly 186 
confident protein identification was set at obtaining a MASCOT total protein score ≥ 187 
50 and at least one peptide e-value of ≤ 0.05. 188 
 189 
RNA extraction.  190 
For planktonic growth conditions, an overnight culture of S. aureus 15981 was diluted 191 
1:100 in an Erlenmeyer flask containing 50 ml of TSBgluc medium and was incubated 192 
to OD600=0.8 at 37°C with shaking. For biofilm growth conditions, microfermentors 193 
where inoculated as described above and incubated at 37ºC for 6 h. Biofilm-grown and 194 
planktonically grown cells were harvested. Total RNA from bacterial pellets was 195 
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extracted by using a TRIzol reagent method (42). Briefly, bacterial pellets were 196 
resuspended into 400 µl of solution A (glucose 10%, Tris 12.5 mM, pH 7.6, EDTA 10 197 
mM), mixed to 60 µl of 0.5M EDTA and transferred into Lysing Matrix B tubes 198 
containing 500 µl of acid phenol (Ambion). Cells were mechanically lysed by using the 199 
Fastprep apparatus (BIO101) at speed 6.0 during 45 s at 4 °C. After centrifugation the 200 
aqueous phase was transferred to 2-ml tubes containing 1 ml of TRIzol and 100 µl of 201 
chloroform. Tubes were centrifuged and the aqueous phase was transferred into a 2-ml 202 
tube containing 200 µl of chloroform, mixed, and incubated for 5 min at room 203 
temperature. Tubes were centrifuged and the aqueous phase containing the RNA was 204 
precipitated by addition of 500 µl of isopropanol and incubation for 15 min at room 205 
temperature. RNA concentrations were quantified, and RNA qualities were determined 206 
by using Agilent RNA Nano LabChips (Agilent Technologies). RNAs were stored at 207 
−80 °C until needed. 208 
 209 
cDNA labeling and DNA microarray hybridization. 210 
Ten µg RNAs were reverse transcribed using SuperScript II reverse transcriptase 211 
(Invitrogen Life Technologies). cDNA was digested by DNase I (PIERCE) in 10X 212 
DNAse I buffer (USB-Affymetrix) and the size of digestion products was analyzed in 213 
the Agilent Bioanalyser 2100 using RNA Nano LabChips to ensure that the 214 
fragmentation resulted in a majority of products in the range of 50 to 200 base-pairs. 215 
The fragmented cDNA were then biotinylated using terminal deoxynucleotidyl 216 
transferase (Promega) and the GeneChip DNA labeling reagent (Affymetrix) following 217 
the manufacturer's recommendations. Biotinylated cDNA (5 microgram per array) were 218 
hybridized to custom S. aureus tiling microarrays designed as described (43) 219 
(ArrayExpress accession: A-AFFY-165) and incubated for 16 h according to the 220 
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Affymetrix protocol in a total volume of 200 µl per hybridization chamber. Following 221 
incubation, the arrays were washed and stained in the Fluidics station 450 (Affymetrix) 222 
using the protocol n°FS450_0005. Scanning of the arrays was then performed using the 223 
GeneChip scanner 3000 (Affymetrix). Intensity signals of each probe cells were 224 
computed by the GeneChip operating software (GCOS) and stored in cell intensity files 225 
(.CEL extension) before preprocessing and analysis. Microarray data were analyzed 226 
using limma package (44). Raw data are available under ArrayExpress accession: E-227 
MEXP-3924. 228 
 229 
Immunization studies. 230 
CD1 mice were obtained from Charles River and maintained in the animal facility of 231 
the Instituto de Agrobiotecnología, Universidad Pública de Navarra. The biofilm matrix 232 
exoprotein extract used for immunization consisted of the exoproteins purified from the 233 
biofilm matrix produced by S. aureus 15981 strain and was referred as BME. Five-234 
week-old female CD1 mice were injected intradermally with 10 µg of BME diluted in 235 
adjuvant (Sigma Adjuvant System®). The control group was treated with PBS and 236 
adjuvant. Two weeks later, the vaccinated group received a booster dose of 5 µg of 237 
BME, while the control group received PBS and adjuvant. Mice were bled via the 238 
retroorbital venous plexus on day 0 (pre-immune serum) and 21 days after the first 239 
vaccination (immune serum). Both serum samples were analyzed by ELISA and 240 
Western Blot for determination of antibody responses against the BME.  241 
 242 
Detection of antibodies in the sera. 243 
Serum IgG and IgM expression against BME were quantified by coating 96-well 244 
ELISA plates (Nunc Maxisorp, Millipore) with 100 µl/well of a 0.1 µg ml-1 BME in 245 
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carbonate buffer (0.5 M; pH 9.4). Plates were incubated at 4ºC overnight. After 246 
incubation, wells were then washed three times with PBS containing 0.1% Tween-20 247 
(PBS-T; pH 7.4) and blocked with blocking buffer (5% nonfat dried milk powder in 248 
PBS-T) at room temperature for 1h. After washing three times with PBS-T, 100 µl of 249 
pre-immune (negative-control) and immune serum diluted 1:100 in PBS were added to 250 
each well and incubated at 37ºC for 2 h. After incubation, wells were washed three 251 
times with PBS-T and 100 µl of HRP-conjugated goat anti-mouse IgG and IgM 252 
(Thermo Scientific) were added to each well. The plates were incubated for 1 h at 37°C 253 
and then washed three times. One hundred µl of ABTS solution (diammonium 2,2'-254 
azinobis[3-ethyl-2,3-dihydrobenzothiazole-6-sulphonate; Millipore) were added to each 255 
well and the absorbance at 405nm was determined on an ELISA reader. Results were 256 
reported as the OD405 of immune serum/OD405 of the control serum (T/C). 257 
Immune response was also determined by Western blot. For that, 5 µg of the BME or a 258 
planktonic culture exoproteins extract were resolved using SDS-polyacrylamide gel 259 
electrophoresis, transferred to a nitrocellulose membrane and incubated with blocking 260 
buffer. Then, the membrane was exposed to pre-immune (negative-control) and 261 
immune serum at 4ºC overnight. After washing five times with washing buffer (PBS-T 262 
0.1%), the membrane was incubated with goat anti-mouse IgG and IgM (H+L) 263 
secondary antibody HRP conjugate and proteins were detected using SuperSignal® 264 
WestPico Chemiluminescent Substrate (Thermo Scientific).  265 
 266 
Opsonophagocytic assays. 267 
Opsonophagocytosis and killing assay has been previously described in (45). Briefly, 1 268 
ml of a planktonic culture of strain S. aureus 132 grown overnight was pelleted for 5 269 
min at 12,000 g at 4°C, washed twice with PBS, and subsequently diluted to an OD600 270 
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of 0.5. Bacteria were pre-incubated with 1% or 10% of immune serum, pre-immune 271 
serum or PBS for 1 h at 4ºC. The opsonophagocytosis assay was performed with fresh 272 
blood obtained from human healthy volunteers. Fresh whole blood from three 273 
volunteers was collected and mixed in tubes containing the anticoagulant heparin and 274 
then aliquoted into 1.5-ml microcentrifuge tubes (0.5 ml/tube). After pre-incubation, 10 275 
µl of bacterial suspensions were added to the 1.5-ml microcentrifuge tubes containing 276 
0.5 ml of fresh blood. Tubes were incubated at room temperature with gentle rocking 277 
and, after 30 min, samples were serially diluted and plated onto TSA plates to 278 
determine the number of surviving CFU. On the other hand, to analyze the 279 
opsonophagocytosis and killing of bacteria that are being part of a biofilm, 0.5x0.5cm 280 
polypropylene meshes (Prolene®) were incubated with an 1:100 overnight dilution of a 281 
culture of the biofilm forming strain S. aureus 132 for 2 hours at 37ºC with shaking. 282 
Meshes were then washed with PBS and pre-incubated with 1% or 10% of immune 283 
serum, pre-immune serum or PBS for 1 h at 4ºC. After pre-incubation, meshes 284 
containing bacteria inside a biofilm were added to the 1.5-ml microcentrifuge tubes 285 
containing 0.5 ml of fresh blood. Tubes were incubated at room temperature with 286 
gentle rocking and, after 30 min, meshes were removed and gently washed and then 287 
placed in 1 ml of PBS and vigorously vortexed. Samples were serially diluted and 288 
plated onto TSA plates for enumeration of viable staphylococci. Four independent 289 
samples of each treatment were performed. The percent amount of bacterial killing was 290 
calculated as [1 - (no. of cfu recovered from the treated samples / no. of cfu recovered 291 
from the PBS control samples)] *100. 292 
 293 
Cytokines production of splenocytes. 294 
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Groups of 5 CD1 mice were immunized as established before in the “Immunization 295 
Studies” section. One week after the second immunization, mice were sacrificed and 296 
their spleens were collected under aseptic conditions. Cells suspensions were prepared 297 
by resuspending the spleens in RPMI 1640 medium supplemented with 10 % heat-298 
inactivated fetal bovine serum and 1 % Penicillin/Streptomycin and subsequent 299 
trituration and filtration through a 70 µm nylon mesh. Red blood cells were lysed using 300 
ACK lysing buffer. Splenocytes were counted and dispensed into 24-well plates at a 301 
concentration of 2 × 105 cells/well. The cells were restimulated with either 1 µg of 302 
BME or with PBS during 24, 48 and 96h. The supernatants were harvested and 303 
analyzed for interleukins IL-10, IL-2, IL17A and gamma interferon production using 304 
their respective ELISA kit (eBioscience) according to the manufacturer´s instructions.  305 
 306 
Vaccination/challenge protocol using an in vivo model of mesh-associated biofilm 307 
infection.  308 
The vaccination protocol was performed as described in the “Immunization Studies” 309 
section using BME, PLKE or 108 heat-killed bacteria emulsified in adjuvant for 310 
immunization. Groups of 6 CD1 mice were used. One week after the second 311 
immunization, a model of mesh-associated biofilm infection was performed as 312 
previously described (46) with the following modifications. Prior to surgical procedure, 313 
0.5x0.5cm polypropylene meshes (Prolene®) were incubated with 0.5 ml of a 1:100 314 
overnight dilution of a culture of the biofilm forming strain S. aureus 132 for 1 hour 315 
and 15 minutes at 37ºC with shaking. To calculate the initial inoculum, duplicate 316 
meshes were placed in 1 ml of PBS and vigorously vortexed. Samples were serially 317 
diluted and plated onto TSA plates for enumeration of viable staphylococci. Control 318 
and vaccinated CD1 mice were anesthetized by intraperitoneal injection of a 319 
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ketamine/xylazine mixture. After abdominal epilation and antisepsis of the operative 320 
field, the animals were operated. An incision of 1.5 cm in the skin was performed with 321 
displacement of the subcutaneous space and opening the peritoneal cavity. Then, a 322 
mesh, coated with 104 CFU of S. aureus strain 132, was fixed at the abdominal wall 323 
with one anchor point. Finally, the peritoneal cavity was closed by suture with 6/0 324 
Monosyn®. The animals were put in a warm environment and when awake, they were 325 
put back in their cages. After 5 days, all animals were sacrificed. Mesh and surrounding 326 
tissue were extracted and placed in 1 ml of PBS and vigorously vortexed. Samples were 327 
serially diluted and plated onto TSA plates for enumeration of viable staphylococci.  328 
To analyze the additional protection against bacterial population that propagates 329 
through detachment from the biofilm, kidneys and liver from the operated animals or 330 
from animals challenged by an intravenous injection of a bacterial suspension 331 
containing 107 CFU of S. aureus Newman, were extracted after 5 days. Viable counts 332 
were performed on the homogenates by plating the samples on TSA.  333 
 334 
335 
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RESULTS 336 
Identification of the S. aureus biofilm matrix exoproteome.  337 
In order to isolate and identify the exoproteins present within the biofilm matrix, the 338 
biofilm formed by the clinical strain S. aureus 15981 grown in TSB-gluc was isolated 339 
(38). This strain forms a PNAG dependent biofilm when grown under the conditions 340 
tested. Exoproteins present within the PNAG-mediated biofilm matrix of 3 independent 341 
samples were purified as described in the materials and methods section. Proteins from 342 
these extracts were precipitated and then separated by 1-D SDS-PAGE followed by 343 
trypsin digestion and identified by 2DnLC-MS/MS. Only proteins identified in at least 344 
two of the three samples were considered for further analysis. Thus, a total of 33 345 
extracellular proteins were detected with a MASCOT score higher than 50 (Table 2). 346 
Importantly, the proteins identified have been recurrently detected in extracellular 347 
proteomes of various S. aureus isolates (34, 47-54). More notably, 28 out of the 33 348 
proteins identified in our analysis have also been found in the biofilm exoproteome of 349 
S. aureus D30 strain, isolated from a persistent nasal carrier (Table 2) (50). These data 350 
reliably support the validity of the method used to identify exoproteins of the biofilm 351 
matrix. 352 
Specifically, exoproteome analyses revealed the presence in the extracellular biofilm 353 
matrix of many proteins involved in pathogenesis such as toxins (leukocidin, EsaA and 354 
truncated beta-hemolysin) or immunomodulatory proteins (lipoprotein, 355 
immunodominant antigen B, immunodominant antigen A, Protein A, IgG-binding 356 
protein, secretory antigen precursor SsaA and SceD). The biofilm matrix also contained 357 
a markedly large number of proteins involved in carbohydrate metabolism, namely 358 
phosphoglycerate mutase, triosephosphate isomerase, enolase, glyceraldehyde-3-359 
phosphate dehydrogenase, glucose-6-phosphate isomerase, alcohol dehydrogenase, L-360 
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lactate dehydrogenase and fructose bisphosphate aldolase. Finally, albeit to a lesser 361 
extent, enzymes involved in cell-wall peptidoglycan synthesis (autolysin and N-362 
acetylmuramoyl-L-alanine amidase), DNA metabolism and stress proteins (foldase 363 
protein, DNA binding protein II, nuclease and superoxide dismutase) were also 364 
encompassed in the biofilm exoproteome.  365 
With the aim of extending the biofilm matrix exoproteome analysis to other S. aureus 366 
strains we used strain 132, which is an MRSA clinical isolate able to alternate between 367 
a PNAG-independent biofilm matrix mediated by the Fibronectin Binding Proteins 368 
(FnBPs) and an exopolysaccharidic PNAG-mediated biofilm depending of whether it is 369 
cultured under TSB-gluc or TSB-NaCl growing conditions, respectively (23). S. aureus 370 
132 was incubated in microfermentors under these two different conditions that 371 
allowed the formation of the two biofilm matrices and subsequently, these were 372 
isolated for matrix exoproteins identification. Analysis of the PNAG-mediated biofilm 373 
matrix revealed the presence of 24 proteins, 17 of which (71%) had been previously 374 
identified in the S. aureus 15981 strain exoproteome. On the other hand, analysis of the 375 
FnBPs-mediated biofilm matrix led to the identification of 19 proteins, being nearly 376 
half of them also present in the exoproteome of the PNAG-mediated matrix, and the 377 
other half in the S. aureus 15981 strain exoproteome. When we considered the biofilm 378 
matrices formed by S. aureus 132 under these two experimental conditions as a unit, 379 
results showed that almost 80% of the matrix exoproteins were included into the 380 
biofilm matrix exoproteome of the S. aureus 15981 strain.    381 
In conclusion, we identified the PNAG-dependent and FnBPs-dependent biofilm matrix 382 
exoproteomes of a methicillin resistant S. aureus isolate and also the PNAG-dependent 383 
exoproteome of a methicillin sensitive clinical strain. The results indicated that 384 
independently of the nature of the biofilm matrix, a common core of secreted proteins 385 
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is contained in both types of exoproteomes. The biofilm matrix exoprotein extract used 386 
for the rest of the study consisted of the 33 exoproteins identified in the biofilm matrix 387 
produced by S. aureus 15981 strain and was referred as BME. 388 
 389 
Transcriptional analysis of genes coding for biofilm matrix exoproteins. 390 
Previous studies with several bacteria have shown that gene expression and protein 391 
production differ when bacteria are grown under biofilm conditions in comparison with 392 
planktonic growth (6-9). Therefore, we proceeded to investigate whether genes coding 393 
for the biofilm matrix exoproteins identified with the proteomic analysis were 394 
differentially expressed in biofilm conditions with respect to planktonic growth. 395 
Transcriptome analyses revealed that S. aureus 15981 cells grown under biofilm 396 
conditions expressed a markedly different repertoire of genes in comparison to their 397 
planktonic counterparts. In total, we observed that 626 genes were differentially 398 
expressed under biofilm growing conditions. From these, 276 genes were expressed in 399 
higher amounts in biofilm cells, whilst 350 genes were down-regulated under biofilm 400 
conditions. Then, we focused on expression levels of the genes coding for the BME 401 
previously identified and found that expression of more than half of the identified 402 
proteins (58%) was up-regulated under biofilm growing conditions (Table 2). 403 
Importantly, genes encoding for 39% of matrix exoproteins were not differentially 404 
expressed under biofilm conditions, indicating that the S. aureus biofilm matrix 405 
encompasses not only proteins that are specific of the biofilm mode of growth, but also 406 
a set of proteins that S. aureus expresses at the same level during planktonic growth.  407 
 408 
Biofilm extracellular proteins induce a humoral immune response in mice. 409 
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In order to investigate whether this multivalent extract might be able to induce a 410 
protective immune response against S. aureus, we firstly evaluated the antibody 411 
response in mice immunized with BME. For that, groups of 8 mice were immunized 412 
with BME. Blood and sera samples were obtained at day 0 and 21 post immunization 413 
and serum IgG and IgM levels were determined by ELISA. Results showed that 414 
immunoglobulin levels were significantly higher in sera from mice immunized with 415 
BME than in sera from control mice (Figure 1A).  416 
Next, BME were separated in a SDS-PAGE gel (Fig. 1B) and interrogated with a pool 417 
of sera obtained either from immunized or control mice. Results showed that the 418 
majority of the biofilm matrix exoproteins were recognized by sera from immunized 419 
mice while only a slight cross-reaction, probably caused by the presence of Protein A, 420 
was observed when sera pool from control mice was used (Figure 1B). Also, because 421 
BME contains a group of proteins that are equally expressed under biofilm or 422 
planktonic growth conditions, we tested immune and control sera against an extract 423 
containing extracellular proteins secreted by S. aureus cells grown planktonically 424 
(PLKE). As expected, immune serum recognized part of the proteins present in the 425 
planktonic extract (Figure 1C).  426 
Finally, with the aim of analyzing if antibodies raised against the BME extract 427 
recognized the biofilm formed by different S. aureus strains we isolated biofilm matrix 428 
exoproteins from biofilms formed by several S. aureus strains and these were 429 
interrogated with immune and control sera. In particular, we tested S. aureus 132 strain 430 
(PNAG and FnBPs mediated biofilms), V329 and Newman::Bap strains (Bap 431 
dependent biofilms) and ISP479 and 12313 strains (PNAG mediated biofilms). As it is 432 
shown in figure 1D, immune sera against the BME extract recognized many proteins 433 
present in all extracts analyzed.  434 
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Taken together, these data showed that BME was able to induce a humoral immune 435 
response and that many of the proteins present in the extract contributed to this 436 
immunogenicity. Also, antibodies generated against BME were capable of targeting a 437 
broad range of biofilm matrices, suggesting that this multivalent extract might be 438 
effective against a large number of relevant biofilm producing strains.  439 
 440 
Antibodies against BME induce opsonophagocytic killing of S. aureus. 441 
The presence of IgG and IgM in the immune serum can be correlated with high opsonic 442 
activity (55). Thus, our next objective was to evaluate whether hyperimmune serum 443 
obtained against BME promoted opsonophagocytic killing of S. aureus. S. aureus 132 444 
strain grown under planktonic or biofilm conditions was pre-incubated with preimmune 445 
serum, 1% or 10% of BME specific sera or PBS as control. After incubation, bacteria 446 
were mixed with whole blood for 30 min (45). Staphylococcal killing was monitored 447 
by spreading sample aliquots on TSA agar medium followed by colony formation and 448 
enumeration. Results showed that antibodies against BME significantly induced 449 
opsonophagocytic killing of both planktonic and sessile S. aureus cells (Figure 2). 450 
Additionally, data showed that killing of biofilm S. aureus cells was slightly higher 451 
than killing of planktonic cells. 452 
 453 
BME induces the production of IL-10 and IL-17 in ex-vivo stimulated splenocytes. 454 
We next sought to characterize the cellular response stimulated by BME. For that, 455 
cytokines production was examined after ex-vivo splenocyte stimulation with BME as 456 
described in the materials and methods section. Supernatants of stimulated cells were 457 
analyzed for the production of IFN- γ and IL-2 (prototypes Th1 cytokines), IL-10 458 
(prototype Th2 cytokines) and Th17-associated cytokine IL-17. When production of 459 
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IL-17 was analyzed over time, a 10 fold increase was observed at the early time of 24 460 
hours post-stimulation, when supernatants of splenocytes coming from mice 461 
immunized with the BME extract where compared to supernatants of control mice 462 
splenocytes. This difference increased to 50 fold at 96 hours post-stimulation (Figure 463 
3). It is important to note that levels of IL-17 over time were barely detectable in 464 
supernatants of control mice splenocytes (Figure 3). With respect to cytokine IL-10, an 465 
approximately 2.5 fold increase was observed at 24 hours post-stimulation that was 466 
maintained over time (P<0.05) (Figure 3). Lastly, mice immunization with BME led to 467 
neither stimulation of cytokine IL-2 production nor induction of IFN-γ (Figure 3). 468 
Taken together, these results showed that immunization with BME induced a cellular 469 
response characterized by production of cytokines IL-17 and IL-10. 470 
 471 
Immunization with BME reduced biofilm formation in a mesh-biofilm model.  472 
We next hypothesized whether immunization with BME might reduce the number of 473 
bacterial cells inside a biofilm formed in-vivo. To analyze this hypothesis, we 474 
compared the efficiency of BME in a mesh-biofilm model with the protective effect of 475 
an extract containing the secreted proteins of S. aureus 15981 grown planktonically 476 
(PLKE) and also, of a heat extract obtained from S. aureus 15981 (HE). Mice were 477 
immunized at an interval of two weeks with 10 µg and 5 µg of the BME, PLKE, 108 478 
heat-killed bacteria (HE) or with adjuvant alone. After immunization, sera from 479 
immunized mice were extracted and were interrogated against the BME proteins. 480 
Results showed that sera from mice immunized with PLKE and HE recognized fewer 481 
proteins of the BME extract than sera from BME immunized mice (Figure 4B). 482 
Seven days after the second immunization, polypropylene meshes coated with 104 CFU 483 
of the biofilm forming strain S. aureus 132 were implanted in the intraperitoneal cavity 484 
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of immunized and control mice. After five days, all animals were sacrificed and meshes 485 
were extracted. When the abdominal cavity of mice was opened, abdominal wall 486 
adhesions were observed in all animals. Meshes removed from non-vaccinated mice 487 
(control) were more difficult to extract from the abdominal cavity than meshes from 488 
vaccinated mice. Also, as it is shown in figure 4C, meshes from control mice were 489 
surrounded by purulent and necrotic tissue, whilst a healthier and a more vascularized 490 
tissue surrounded the meshes coming from immunized mice. When the number of 491 
bacteria on meshes was determined, results showed that immunization with BME 492 
significantly reduced the number of bacteria attached to the polypropylene meshes 493 
(P≤0.05) (Figure 4A). In contrast, immunization with PLKE or HE showed a slight but 494 
not statistically significant reduction of the number of bacteria in the mesh-biofilm 495 
model (Figure 4A). 496 
Finally, we decided to investigate whether BME vaccinated mice were additionally 497 
protected against bacterial population that propagates via detachment from the biofilm. 498 
To do so, mesh-surrounding tissue, kidneys and liver from BME immunized mice were 499 
extracted and bacterial colonization was determined. In contrast to the non-vaccinated 500 
group (control), mice immunized with BME presented a significantly reduced number 501 
of bacteria in liver and mesh-surrounding tissue (P≤0.05) (Figure 4D). Although there 502 
was also a slight reduction in kidney colonization in immunized mice, differences 503 
between control and vaccinated mice were not statistically significant (P=0.06) (Figure 504 
4D).  505 
Reduction in organ colonization in immunized mice might be the consequence of not 506 
only reduction of biofilm formation capacity inside the animal and thus, a reduction in 507 
the number of released bacteria from the biofilm, but also the efficacy of the immune 508 
response against organ colonization by released bacteria. In order to analyze this 509 
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possibility, we tested whether vaccination with the exoproteins extract might protect 510 
against a systemic infection and subsequent organ colonization caused by S. aureus. 511 
For this, mice were immunized as above and were challenged with a retroorbital 512 
injection containing 107 cfu/mice of S. aureus. Five days after the infection, animals 513 
were killed and kidneys and livers were removed. No bacteria were found in the liver 514 
of either vaccinated or control mice. Contrary, visual examination of kidneys from non-515 
vaccinated mice showed the presence of abscesses all around the surface of the organs. 516 
Much fewer abscesses were detected on kidneys from immunized mice (Figure 5). 517 
Enumeration of S. aureus cells from the organs showed that kidneys of immunized 518 
mice were significantly less colonized than kidneys of control mice (P<0.01) (Figure 519 
5).  520 
From all these results we inferred that immunization with BME significantly reduced 521 
biofilm formation in an in vivo model of mesh-associated biofilm infection and also 522 
moderated organ colonization conducted by bacteria that were released via detachment 523 
from the biofilm. 524 
525 
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DISCUSSION 526 
In the last years, S. aureus has emerged as one of the most critical nosocomial 527 
pathogens. Success of S. aureus as a pathogen is the result of different abilities such as 528 
the capacity to invade a wide variety of cell types, to secrete a diversity of proteins and 529 
toxins and to persist in the host remaining resistant to clearance by the immune system 530 
or antibiotics through a biofilm mode of growth. Numerous approaches have been 531 
adopted in order to identify staphylococcal surface and cell wall associated proteins as 532 
antigenic candidates for a vaccine against S. aureus infections (34, 49, 51, 53, 56-60). 533 
However, few works have been focused on the selection of antigens that could also 534 
protect against biofilm-associated bacteria (14, 24-26). This is particularly important 535 
because S. aureus biofilms play a major role in persistent infections formed on the 536 
surface of implanted medical devices and in deep tissues. In this study we have 537 
demonstrated that a multicomponent extract containing biofilm matrix exoproteins is 538 
able to elicit a protective immune response against S. aureus biofilm-mediated 539 
infections.  540 
According to Harro et al (36), the selection of appropriate antigens effective in 541 
preventing the establishment of a biofilm related infection should meet the following 542 
criteria: (i) they must be expressed in vivo throughout the infection cycle in a large 543 
number of genetically unrelated strains; (ii) they must target the entire microbial 544 
population of the biofilm; and (iii) they must also induce a protective immune response 545 
against planktonic bacteria. 546 
Numerous evidence have demonstrated that S. aureus is able to produce 547 
polysaccharidic and proteinaceous biofilm matrices (11-16). Therefore potential 548 
antigens against S. aureus biofilm infections should be expressed by strains that form 549 
either type of biofilm matrix. Our results showed that BME extracted from 550 
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exopolysaccharidic matrices of two unrelated clinical strains (S. aureus 15981 and 132) 551 
comprised a high number of proteins in common. Moreover, all proteins except one 552 
present in the BME isolated from a proteinaceous matrix produced by S. aureus 132 553 
were also contained in PNAG-dependent matrices (Table 2). Also, it is important to 554 
note that 85% of exoproteins encompassed in the BME of S. aureus 15981 are identical 555 
to the first S. aureus biofilm exoproteome identified and produced by the nasal carrier 556 
strain S. aureus D30 (50). Accordingly, here we showed that antibodies raised against 557 
an extract coming from a PNAG-dependent biofilm formed by strain 15981 recognized 558 
many proteins from biofilms of different nature produced by different S. aureus strains 559 
(Figure 1D). These data might explain why immunization with a BME extract obtained 560 
from strain 15981 was effective to protect against a challenge with the clinical relevant 561 
MRSA strain S. aureus 132 (Figure 4) and with S. aureus Newman strain (Figure 5). 562 
Because individual cells within biofilms can display different protein expression 563 
patterns depending on nutrient availability, respiratory conditions or environmental 564 
stresses, Harro et al (36) proposed that vaccines that only aim at one specific antigen 565 
would likely eliminate the section of the biofilm in which the antigen is expressed, 566 
whereas, other biofilm areas that do not express the vaccinated antigen will probably 567 
persist. Hence, BME extract comprising most exoproteins of the biofilm matrix may 568 
ensure that not only different areas of the biofilm but also various cell types present 569 
within the biofilm are targeted. It is important to note that vaccination with other 570 
multicomponent extracts such as a heat-killed or a PLKE extract, which have been 571 
shown to provide protection against S. aureus infections (41, 61, 62), were less efficient 572 
than BME to reduce the number of bacteria inside a biofilm, using a mesh associated 573 
biofilm infection model. The reason behind the low efficiency of heat-killed and PLKE 574 
extracts might be that they probably do not enclose biofilm specific antigens as the 575 
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BME extract (Figure 4). Additional experimentation will be required to arrive at a 576 
detailed picture of the localization of BME proteins into the biofilm structure. 577 
Biofilm formation is a dynamic process that occurs through sequential steps in which 578 
the initial attachment of planktonic bacteria to a surface is followed by their subsequent 579 
proliferation and accumulation in multilayer cell clusters where bacteria are enclosed in 580 
a self-produced polymeric matrix. As biofilm ages, bacterial cells escape from the 581 
matrix and return to a planktonic existence, being able to reach other locations in the 582 
host. This step represents a potentially important mechanism for the dissemination of 583 
bacteria during infection. Our proteomic, transcriptomic and immunological analysis 584 
showed that BME extract contains antigens that S. aureus produces under both 585 
planktonic and biofilm growing conditions (Table 2). As a consequence, sera from 586 
BME immunized mice recognized several proteins in the exoproteome extract of 587 
planktonic bacteria (Fig. 1C). Accordingly, mice immunized with this extract not only 588 
showed a reduction in the number of bacteria inside a S. aureus biofilm but also 589 
moderated tissue and organ colonization by bacteria that were released through 590 
detachment from the biofilm. Nevertheless, clearance of the infection would likely 591 
require an added antimicrobial treatment as it has been already proposed by Brady et al 592 
(37).   593 
With respect to the immune response mounted after mice immunization with BME, 594 
results showed an increase in the production of total immunoglobulins. The primary 595 
antibodies function in the protection against S. aureus infections is neutralization and 596 
opsonization of bacteria for phagocytosis. Although reduction in the number of biofilm 597 
bacteria on PS-meshes in the opsonophagocyitc experiment could be due to both 598 
neutralization and the opsonic activity of antibodies, we did not observe a significant 599 
direct effect of BME-antibodies on S. aureus biofilms in vitro, in the absence of 600 
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immune system components (Supplementary Figure 1). Hence, BME-antibodies seem 601 
to protect against S. aureus infections likely through an increase in opsonization. 602 
Importantly, these opsonic antibodies may help in the phagocytosis of bacteria inside a 603 
biofilm that otherwise would be inaccessible due to the extracellular matrix coating. 604 
Although antibodies unquestionably play an important role in the protection against S. 605 
aureus infections, they may not be decisive for vaccine protective efficacy since 606 
animals and humans have enough circulating antibodies to S. aureus (56, 63, 64). 607 
Certain indications show a partial role of these antibodies in protecting humans against 608 
staphylococcal infections (65). However, patients with defects in humoral immunity are 609 
not particularly prone to S. aureus infections (66). In this respect, a cellular response 610 
mediated by interleukin IL-17 is being considered critical for immunity against this 611 
pathogen. It has been shown that vaccination with heat killed S. aureus provides 612 
protection in systemic infection via staphylococcal lipoproteins that stimulate Th17/IL-613 
17 (67). Also, IL-17 induction has been shown to be determinant in the clearance of 614 
IsdB-immunized mice (68). In biofilm-related infections, IL-17 cytokine production 615 
increases during the development of the infection, indicating that infected mice mount a 616 
robust Th17 response (69, 70). Bacteria in biofilm are embedded in an extracellular 617 
matrix and are largely protected from phagocytosis by neutrophils and macrophages. 618 
The release of inflammatory cytokines by Th17 cells provokes the recruitment and 619 
activation of neutrophils and might aid to devitalize the biofilm surface helping to 620 
bacterial clearance. In the case of BME extract immunization, it did not only induce a 621 
humoral response but also stimulated the production of IL-17 that might help to clear 622 
bacteria in the biofilm. In order to elucidate the role of the induction of IL-17 by BME 623 
administration in the efficiency of this multicomponent extract, we have performed a 624 
preliminary experiment in which IL-17 cytokine was neutralized by administration of 625 
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an antibody against IL-17. BME-immunized mice that had been administered the 626 
neutralizing antibody to IL-17 showed non-significant reduction in the number of 627 
bacteria recovered from biofilm-infected meshes when compared with control BME-628 
immunized mice (Supplementary Figure 2). These preliminary results suggest a 629 
putative role of IL-17 cytokine in the immune response against a S. aureus biofilm 630 
related infection. BME immunized mice presented also significantly higher levels of 631 
IL-10 compared to non-vaccinated mice. IL-10 cytokine has been shown to protect the 632 
host from staphylococcal enterotoxin, endotoxin and septic shock (71-73). 633 
Furthermore, administration of an anti-IL-10 monoclonal antibody to mice inhibits the 634 
clearance of S. aureus, suggesting that IL-10 might play a beneficial role in host 635 
resistance to S. aureus systemic infections (74, 75). Further studies are needed to 636 
explore the role of IL-10 induction by BME administration in the clearance of S. aureus 637 
biofilm-related infections.  638 
In summary, the work presented here shows that an extract containing biofilm matrix 639 
exoproteins induces a protective immune response against a S. aureus biofilm related 640 
infection and thus reduces colonization and persistence. This is likely because this 641 
multicomponent vaccine ties together cell-mediate immunity and a humoral response 642 
where opsonic antibodies play a supportive role to eradicate the biofilm infection. In 643 
future work, it would be interesting to determine the contribution of each antigen 644 
present in the BME extract to its immunogenicity in order to define a particular antigen 645 
combination that provides efficient protection against S. aureus biofilm infections.  646 
     647 
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Table 1. Bacterial strains 926 
 927 
 928 
Strains Relevant characteristic(s) Reference or 
source 
S. aureus 15981 MSSA clinical strain.  
Biofilm positive; PNAG-dependent biofilm matrix 
(38) 
S. aureus 132 MRSA clinical strain. 
Biofilm positive, able to alternate between a protein-
dependent biofilm matrix (grown in TSB-gluc) and a 
PNAG-dependent biofilm matrix (grown in TSB-NaCl) 
(23) 
S. aureus ISP479c MSSA clinical strain.  
Biofilm positive; PNAG-dependent biofilm matrix 
(76) 
S. aureus 12313 MSSA clinical strain.  
Biofilm positive; PNAG-dependent biofilm matrix 
(23) 
S. aureus V329 Bovine subclinical mastitis isolate.  
Biofilm positive; protein-dependent biofilm matrix 
(19) 
S. aureus Newman Strain used in systemic infection models (77) 
 929 
  930 
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Table 2. Biofilm matrix exoproteomes 931 
 932 
GenBank accession no. Putative Protein  S. aureus 15981 
S. aureus 
132-PNAG 
S. aureus 
132-FnBPs Theoric PI 
Theoric 
Mw(10-3)  Total score
a   Coverage % RatioExp
b 
Exoproteins up-regulated under biofilm conditions 
gi15927581c SA1813 Leukocidin x   9.43 40.43 140.5 4.57 32.8 
gi15926283c SA0562 Alcohol dehydrogenase Adh1 x x  5.34 36.05 113.51 10.12 16.6 
gi15923805c SA0746 Nuclease x x x 9.27 25.12 1306.41 25.44 14 
gi15926008c SA0295 Lipoprotein  x  x 9.49 33.35 321.51 17.15 7.8 
gi15927994c SA2204 Phosphoglyceromutase GpmA x  x 5.23 26.68 191.13 7.02 7.7 
gi15928224c SA2431  Immunodominant antigen B IsaB x  x 9.67 19.37 1995,27 21.14 7.6 
g15925815c SA0107 Protein A x   5.54 56.44 289.57 13.78 6.9 
gi15927579 SA1811 Truncated beta-hemolysin Hlb x  x 7.68 31.26 463.98 6.57 5.9 
gi15926570 SA0841 MAP hypothetical protein  x x x 9.28 15.84 2018.96 18.06 5.7 
gi15925596c SA2399 Fructose-1,6-bisphosphate aldolase x x  4.88 33.04 376.91 10.14 4.1 
gi15926551c SA0823 Glucose-6-phosphate isomerase Pgi x x  4.83 49.82 69.43 8.8 3 
gi15926634 SA0900 Cysteine protease precursor SspB  x  x 5.68 44.52 1662.70 24.68 2.9 
gi15926265 SA0544 Hypothetical protein   x 
x 5.12 29.39 143.28 5.2 2.8 
gi15927415c SA1659 Foldase protein PrsA x x  9.01 38.64 105.90 3.44 2.8 
gi15926291c SA0570 Hypothetical protein  x  x 9.17 18.59 557.99 23.81 2.7 
gi15927996c SA2206 IgG-binding protein SBI x  x 9.38 50.07 172.37 5.87 2.6 
gi15927419c SA1663 Hypothetical protein x x  4.33 13.31 227.81 34.21 2.6 
gi15925985c SA0272 Type VII secretion protein EsaA x   6.24 114.78 99.62 1.19 2.5 
gi15926635c SA0901 Serine protease SspA x   5.00 36.97 421.27 12.69 2.3 
gi15926639c SA0905 Autolysin Atl x  x 9.60 136.75 3160.15 24.68 2 
Exoproteins non-differentially expressed 
gi15926452c SA0730 Phosphoglycerate mutase Pgm x   4.74 56.42 495.22 16.23 1.8 
gi15926451c SA0729 Triosephosphate isomerase TpiA x x x 4.80 27.29 225.47 24.51 1.8 
gi15926453c SA0731 Enolase Eno x x  4.55 47.12 468.17 7.83 1.7 
gi15923272c SA0271  Hypothetical protein  x   4.61 11.04 2443.79 74.23 1.6 
gi15926190c SA0471 Cystein synthase CysK  x  5.37 32.97 243.53 7.74 1.6 
gi15926073c SA0359 Putative secreted protease inhibitor    x  5.70 21.27 82.70 6.32 1.5 
gi15928230c SA2437 N-acetylmuramoyl-L-alanine amidase  x   5.96 69.25 80.54 2.91 1.4 
gi15928076c SA2285 Cell wall surface protein SasG  x 
 5.35 178.53 73.21 1.93 1.4 
gi15926396 SA0674 Sulfatase x x x 9.04 74.4 1308.21 4.64 1.3 
gi15927054c SA1305 DNA-binding protein II  x  x 9.52 9.63 676.57 52.22 1.2 
gi15926091 SA0375 Inositol-monophosphate dehydrogenase  x  4.49 55.81 52.29 2.25 1.2 
 37 
gi15927699c SA1927 Fructose-bisphosphate aldolase FbaA x x  5.01 30.84 776.38 19.23 1.1 
gi15926449c SA0727 Glyceraldehyde-3-phosphate dehydrogenase  x x x 4.89 36.28 604.09 19.94 1.1 
gi15926679c SA0944 Pyruvate dehydrogenase E1 PdhB  x  4.65 35.24 74.69 10.46 1.1 
gi15928148c SA2356 Immunodominant antigen A IsaA x x x 6.11 24.2 424.96 23.18 1 
g15927884 SA2097 Hypothetical protein    
x 5.77 17.4 65.96 9.2 1 
gi15925944c SA0232 L-lactate dehydrogenase LctE x x x 4.95 29.45 98.7 11.04 -1 
gi15926229 SA0509 Chaperone protein HchA  x  4.90 32.17 95.91 5.14 -1.1 
gi15927133c SA1382 Superoxide dismutase SodA x x x 5.08 22.71 3457.35 31.65 -1.1 
gi15927879c SA2093 Secretory antigen precursor SsaA homolog  x x  8.96 29.33 324.85 22.85 -1.9 
Exoproteins down-regulated under biofilm conditions 
gi15927670 SA1898 Similar to SceD precursor x x  5.52 24.07 57.82 7.79 -4.2 
a MASCOT score obtained by2D-LC-MS/MS analysis  933 
b Ratio of gene expression levels between biofilm and planktonic growth conditions 934 
c Also found in S. aureus D30 biofilm exoproteome by (50). 935 
 936 
 937 
  938 
 38 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
 946 
 947 
 948 
 949 
 950 
 951 
 952 
 953 
 954 
 955 
 956 
 957 
 958 
 959 
 960 
 961 
 962 
 963 
 964 
Figure 1: Immunogenicity of the BME extract in mice. Mice (n = 8) were immunized 965 
twice at an interval of 2 weeks with 10 and 5 µg of the BME extract (treated serum) or 966 
with the adjuvant alone (control serum). Sera were collected at times 0 and 1 week 967 
after the last immunization. A) IgG titers in response to mice immunization were 968 
determined by ELISA. Results were reported as the OD405 of immune serum 969 
(treated)/OD405 of the control serum (control) (T/C). The biofilm matrix exoprotein 970 
extract (BME) (B) and a protein extract (PLKE) coming from the supernatant of a 971 
planktonic culture (C) were separated on a SDS gel and silver stained. Proteins were 972 
transferred to a nitrocellulose membrane by western-blotting and probed with immune 973 
or control serum and detected with goat anti-mouse IgG and IgM (H+L) secondary 974 
antibody HRP conjugated. (D) Western Blot analysis of matrix exoproteins extracts of 975 
biofilms formed by different S. aureus strains, probed with immune and control serum. 976 
S. aureus ISP479r (ISPr); S. aureus 12313; S. aureus V329; S. aureus Newman_Bap 977 
(Nw-Bap)  978 
 39 
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 986 
 987 
Figure 2: Opsonization with immune serum against BME enhances killing of S. 988 
aureus. Bacteria grown in planktonic form (white) or attached to polypropylene 989 
meshes (grey) were tested for their ability to survive in human blood after 990 
preincubation with sterile PBS, preimmune serum, 1% or 10% of immune serum. 991 
Surviving bacteria were measured by viable counting. Results are expressed as % of 992 
killing calculated as [1 - (no. of cfu recovered from treated samples / no. of cfu 993 
recovered from PBS control samples)] *100. Multiple comparisons were performed by 994 
one-way analysis of variance combined with the Bonferroni multiple comparison test. 995 
GraphPad Instat, version 5). 996 
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Figure 3: BME-induced production of cytokines in splenocytes. Mice were 1013 
immunized twice at an interval of 2 weeks with 10 and 5 µg of the BME extract 1014 
(treated) or with adjuvant alone (control). Three weeks postimmunization, splenocytes 1015 
were harvested and restimulated for 24h, 48h and 96h with 1 µg of the BME extract. 1016 
Cell supernatants were harvested and analyzed for IL-2, IL-10, IL17 and IFN-γ 1017 
production using respective ELISA kits. Results are expressed as pg/ml of each 1018 
cytokine and are representative of three independent samples. Statistical analysis was 1019 
carried out using the unpaired Student t test. 1020 
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Figure 4: BME extract protects against a biofilm related infection. A) Mice were 1038 
immunized twice at an interval of 2 weeks with 10 and 5 µg of the BME, PLKE, 108 1039 
heat-killed bacteria (HE) or with adjuvant alone (control). Polypropylene meshes 1040 
coated with 104 CFU of S. aureus strain 132 were fixated at the abdominal wall. After 1041 
5 days, animals were sacrificed and meshes were extracted and placed in 1 ml of PBS. 1042 
Samples were serially diluted and plated onto TSA plates for enumeration of viable 1043 
staphylococci. Results are representative of six independent mice. Multiple 1044 
comparisons were performed by one-way analysis of variance combined with the 1045 
Bonferroni multiple comparison test. (GraphPad Instat, version 5). B) BME proteins 1046 
were transferred to a nitrocellulose membrane by western-blotting and probed with 1047 
sera purified from mice immunized with BME, PLKE or HE. C) Images of biofilm 1048 
infected meshes after 5 days of infection. D) Vaccination with the BME extract also 1049 
reduces colonization by bacteria that are released from the biofilm. Liver, kidneys and 1050 
mesh-surrounding tissue from vaccinated and control mice were extracted after five 1051 
days of insertion of contaminated meshes. Viable staphylococci in the organs and 1052 
tissue were determined by plate counting. 1053 
 1054 
  1055 
 42 
 1056 
 1057 
 1058 
 1059 
 1060 
 1061 
 1062 
 1063 
 1064 
 1065 
 1066 
 1067 
Figure 5: Immunization with the BME extract generates a significant protective 1068 
immunity against S. aureus infection. Vaccinated and control mice were infected with 1069 
a retrorbital injection containing 107 CFU of S. aureus Newman. Viable counts were 1070 
performed on kidney homogenates by plating the samples on TSA. At the bottom, 1071 
images of abscesses (black arrows) formed in kidneys from control and vaccinated 1072 
mice are shown 1073 
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